ARID1A is a recently identified tumor suppressor that functions in chromatin remodeling. Inactivating mutations of ARID1A and loss of its expression most frequently occur in ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma. In this study, we performed a detailed immunostaining analysis of ARID1A in 246 cases including benign endometrium and endometrioid carcinoma at different stages of progression. Special attention was paid to recording intratumoral heterogeneity of clonal loss of ARID1A immunoreactivity. All normal endometria (n = 51) and endometrial polyps (n = 14) retained ARID1A expression. Among complex atypical hyperplasias (n = 38), 16% exhibited clonal loss of ARID1A, but none showed complete loss. Among low-grade endometrioid carcinomas (n = 88), 25% exhibited complete loss and 24% exhibited clonal loss. In contrast, 44% of high-grade endometrioid carcinomas (n = 55) showed complete loss of ARID1A, and 9% exhibited clonal loss. We found that 19 high-grade carcinomas also contained concurrent low-grade carcinomas. In the high-grade areas, 63% exhibited complete loss and 11% exhibited clonal loss, whereas in the low-grade areas, 37% exhibited complete loss and 42% clonal loss. In 5 of these 19 cases, progressive loss of ARID1A from retention or clonal loss to complete loss was observed between the low-grade and high-grade areas. Overall, the percentage of complete ARID1A loss increased from 0% in complex atypical hyperplasia, to 25% in low-grade endometrioid carcinoma, to 44% in high-grade endometrioid carcinoma. These findings suggest that loss of ARID1A expression, presumably due to mutation, plays an important role in tumor progression of uterine endometrioid carcinoma.
A ccess of nuclear factors and enzymes to nucleosomefree DNA is required for a plethora of nuclear activities involving transcription, DNA replication, methylation, and damage repair. This is made possible by chromatin remodeling complexes that facilitate moving and displacing histones along the DNA strand to create nucleosome-free chromosomal regions where those processes can occur. Cancer cells exploit aberrations in chromatin remodeling to drive tumor initiation and progression by a process in which somatic mutations inactivate genes encoding proteins that participate in SWI/ SNF (SWItch/Sucrose NonFermentable) chromatin remodeling. These genes include ARID1A (BAF250A) in endometrium-related carcinoma, 1-3 ARID2 in hepatocellular carcinoma, 4 PBRM1 (BAF180) in renal cell carcinoma, 5 and BRG1 (SMARCA4) in lung cancer. 6, 7 On the basis of whole-exome sequencing, we have previously reported frequent somatic mutations of ARID1A in ovarian clear cell carcinomas. 2 Subsequent studies further showed that ARID1A mutations are present in several types of cancer including ovarian endometrioid carcinoma, uterine endometrioid carcinoma, and several other types of carcinoma. [8] [9] [10] We found that ARID1A mutations occur in 40% of FIGO grade 1 uterine endometrioid carcinomas, 1 and this result was validated by a recent study using whole-exome sequencing. 11 Thus, it appears that ARID1A somatic mutations occur most frequently in endometriosis-related ovarian carcinoma 12 and uterine endometrioid carcinoma.
Expression of ARID1A has also been studied in uterine endometrioid carcinomas, and loss of ARID1A expression correlated with ARID1A mutation and was found in 26% of grade 1 endometrioid carcinomas. 1 In a comparison of low-grade (FIGO grades 1 and 2) endometrioid carcinoma and high-grade (FIGO grade 3) endometrioid carcinoma, Wiegand et al 13 found a higher percentage of ARID1A loss in high-grade (39%) than in low-grade endometrioid carcinoma (29%). However, ARID1A expression in normal endometrium and benign lesions such as endometrial polyps and hyperplasia was not fully assessed, and a direct comparison of concurrent low-grade and high-grade endometrioid carcinomas has not been reported. In order to extend these previous reports of ARID1A expression in uterine endometrioid carcinoma, we conducted a comprehensive study analyzing ARID1A staining at different stages of tumor progression from normal endometrium, hyperplasia, low-grade endometrioid carcinoma, and high-grade endometrioid carcinoma. We have paid special attention to reporting complete versus clonal loss in these cases.
MATERIALS AND METHODS

Tissue Material
Normal endometrial tissues included proliferative endometrium (n = 29), secretory endometrium (n = 16), atrophic endometrium (n = 4), and gestational endometrium (n = 2). In addition, endometrial polyps (n = 14) and complex atypical hyperplasia (CAH) (n = 38) were also studied. The specimens were acquired by either curettage or hysterectomy and were obtained from the National Taiwan University Hospital. It is noteworthy that 10 of the 29 proliferative endometrium specimens showed features of disordered proliferative endometrium. Among 38 cases of CAH, 35 were from endometrial curettage, and subsequent hysterectomy was performed in 19 of them. A total of 88 low-grade (FIGO 1 and 2) and 55 high-grade (FIGO 3) endometrioid carcinomas from total hysterectomies were retrieved from the National Taiwan University Hospital and the Johns Hopkins Hospital, Baltimore, MD. Hematoxylin and eosin-stained slides were rereviewed (by T-L.M. and I-M.S.) to confirm the diagnoses. Fifty-eight of the low-grade endometrioid carcinomas were from our previous study. 1 In high-grade carcinoma, a concurrent low-grade component (usually FIGO 1) was recorded when there was a discrete area exhibiting an abrupt change in tumor grade without gradual transition. The age of patients with high-grade endometrioid carcinoma ranged from 33 to 83 years, with a mean of 56 years. FIGO staging was known in 49 carcinomas, and among them, 25 were stage I, 6 were stage II, 14 were stage III, and 4 were stage IV.
Immunohistochemistry
Eighty-eight low-grade endometrioid carcinomas and 55 high-grade endometrioid carcinomas including 36 pure high-grade carcinomas and 19 mixed high-grade and low-grade carcinomas were evaluated for ARID1A immunoreactivity. Immunohistochemical staining of ARID1A was performed on at least 1 and as many as 10 blocks per case, depending on their availability. For highgrade (grade 3) carcinomas with a concurrent low-grade component, staining was performed on both components. When there was discordant staining between the lowgrade and high-grade components, the rest of the available blocks were further stained. Collection of specimens and immunohistochemical analysis were performed under approval by the Institutional Review Board at the National Taiwan University Hospital.
Immunohistochemical analysis was performed first by autoclaving tissue sections at 1201C for 10 minutes in citrate buffer (pH 6.0). Tissue sections were then incubated with the primary antibody (ARID1A; Sigma-Aldrich; HPA005456, polyclonal, 1:250) at 41C overnight. The specificity of the ARID1A antibody has been previously demonstrated. 1 Immunoreactivity was detected using EnVision+System (Dako, Carpinteria, CA). Only nuclear staining was considered positive. Stromal cells within each section served as a positive internal control. Complete loss was defined as the absence of ARID1A immunoreactivity in virtually all tumor cells, whereas clonal loss was defined as the lack of staining in a discrete tumor area(s) against a background of ARID1A-positive tumor cells. When there was clonal loss, the percentage of the area with clonal loss was estimated on the basis of the staining result of the available blocks. Sporadic single-gland loss was defined as loss of staining involving 1 or 2 individual glands while the rest of the glands were positive.
Statistical Analysis
Differences in the patterns of ARID1A expression among different groups were assessed using the Fisher exact test; P < 0.05 was considered significant.
RESULTS
ARID1A Staining Patterns in Normal and Benign Endometrium
All normal endometrium specimens and benign endometrial polyps at different phases of hormonal activity demonstrated diffuse and intense ARID1A immunoreactivity, and none of them exhibited either complete or clonal loss of ARID1A staining (Table 1) . Sporadic loss of ARID1A staining was observed in 4 cases, but the loss only involved 1 or 2 individual glands ( Fig. 1A ). Those 4 specimens included 2 cases of proliferative endometrium, 1 disordered proliferative endometrium, and 1 endometrial polyp with proliferative activity (Table 1) . Staining on deeper sections of the same tissue blocks did not reveal additional areas showing ARID1A loss in the endometrial glands.
ARID1A Staining Patterns in CAH
Next, we examined ARID1A staining in CAH, which is associated with increased risk in developing endometrioid carcinoma 14 of the uterus. Among the 38 cases of CAH, 27 had retention of ARID1A, 5 cases exhibited sporadic loss in single glands ( Fig. 1B ) and 6 exhibited focal clonal loss (Fig. 1C ). Further staining on the deeper sections of the 5 cases with sporadic loss in 
ARID1A Staining Patterns in High-grade Uterine Endometrioid Carcinoma
As compared with normal, benign, and hyperplastic endometrium, high-grade endometrioid carcinomas exhibited several different patterns of ARID1A staining. First, among 55 high-grade endometrioid carcinomas, complete loss of ARID1A was detected in 24 (44%), and clonal loss was detected in 5 (9%), whereas ARID1A retention was found in 26 (47%). Among the 5 tumors with clonal loss, 2 had concurrent low-grade components. The areas with clonal loss comprised from <10% to as much as 50% of the high-grade component. One tumor without a concurrent low-grade component exhibited 2 patterns of ARID1A expression-approximately half of the tumor contained diffuse and intense ARID1A staining, whereas the other half had completely lost ARID1A positivity (Fig. 2B ). Among the 26 ARID1A-positive carcinomas, 24 exhibited diffuse and intense ARID1A staining, whereas 2 tumors had much weaker ARID1A staining. In contrast to some normal and hyperplastic endometrium specimens, none of the 26 ARID1A-positive cases exhibited focal sporadic loss. There were 19 high-grade endometrioid carcinomas containing concurrent low-grade endometrioid carcinomas. Among these, complete loss of ARID1A was found in 12 (63%) high-grade components and 7 (37%) low-grade components. Clonal loss was observed in 2 (11%) high-grade components and 8 (42%) low-grade components ( Table 2 ; Fig. 3 ). By comparing the high-grade and low-grade components from individual patients, we observed a progressive loss of ARID1A expression in 5 of the 19 tumors with concurrent low-grade components: 4 tumors had ARID1A clonal loss, and 1 tumor had ARID1A retention in the low-grade component, whereas the highgrade component of all 5 tumors had complete loss. The ARID1A staining pattern from 1 of these cases is shown in Figure 3B . Among the remaining 14 high-grade endometrioid carcinomas containing concurrent low-grade endometrioid carcinomas, 12 exhibited concordant expression patterns of ARID1A, but the remaining 2 exhibited an opposite pattern in which the high-grade component retained ARID1A staining and the low-grade component exhibited clonal loss.
The Pattern of Loss of ARID1A Immunoreactivity in Different Stages of Tumor Progression in Endometrioid Carcinoma
As we have applied the same ARID1A antibody and method of immunohistochemistry in assessing ARI-D1A expression in 58 low-grade (FIGO grades 1 and 2) 1 and an additional 30 low-grade endometrioid carcinomas in this study, we combined the previous data with the current results in order to generate an overview of changes of ARID1A staining patterns in normal and abnormal endometrium. Three staining patterns were used: complete loss, clonal loss, and no loss of ARID1A immunoreactivity. Complete and clonal loss was found in 22 (25%) and 21 (24%) of 88 low-grade endometrioid carcinomas, respectively. We observed a progressive decrease in the percentage of cases with "no loss" as we moved from normal endometrium (including benign Am J Surg Pathol Volume 37, Number 9, September 2013
Loss of ARID1A Expression in Endometrioid Carcinoma endometrial polyps) to high-grade endometrioid carcinoma. A significant progressive increase in the percentage of cases showing "complete loss" was observed as we moved from normal or hyperplastic endometrium to lowgrade and then to high-grade endometrioid carcinoma ( Fig. 4 ). Clonal loss of ARID1A expression was present in CAH and in low-grade and high-grade endometrioid carcinoma, but the percentage of cases exhibiting clonal loss was lower in high-grade endometrioid carcinoma than in CAH and low-grade endometrioid carcinoma. Complete loss of ARID1A was not observed in benign endometrium and CAH.
DISCUSSION
In this study, we compared the ARID1A staining patterns among different progression stages of uterine endometrioid carcinoma from normal endometrium, to hyperplastic endometrium, to low-grade endometrioid carcinoma, to high-grade endometrioid carcinoma. We found that there was a significant increase in the percentage of cases demonstrating complete loss of ARID1A expression accompanied by a gradual decrease in the percentages of cases showing no loss of ARID1A immunoreactivity during tumor progression. As ARID1A is a tumor suppressor, and loss of its expression has been demonstrated to result in increased cellular proliferation, 15 our results suggest an important role of ARID1A inactivation in the pathogenesis of uterine endometrioid carcinoma and should have several biological and translational implications.
Loss of ARID1A expression appears as early as the stage of CAH, presenting as a form of "clonal loss," in which negative ARID1A immunoreactivity, presumably due to an inactivating mutation, is only present in a small cluster of individual glands. It is plausible that these emerging ARID1A-negative clones eventually outgrow the surrounding ARID1A-positive tumor cells, because loss of ARID1A expression confers an increased proliferative activity compared with tumor cells without loss of ARID1A expression. 15 As a result of clonal expansion, ARID1A-negative glands prevail in the tumor, resulting in complete loss of ARID1A as time goes by. Interestingly, we found ARID1A loss in a single gland in benign endometrium (an example shown in Fig. 1A ). As each endometrial gland develops clonally, 16 our result suggests that loss of ARID1A expression, presumably due to inactivating mutations, occurs in the endometrial stem cells that subsequently populate the whole gland. This finding is similar to the observation of PTEN loss in normal endometrium 17 and that molecular changes affecting expression of tumor suppressors, ARID1A and PTEN, precede morphologic changes in endometrial epithelial cells. It can be envisioned that the time window from clonal loss to complete loss of ARID1A may be small, as suggested by the observation that all endometrioid carcinomas with ARID1A loss exhibited either clonal or complete loss, with the exception of 1 case, which exhibited ARID1A loss in half of the tumor (Fig. 2B ). It has been demonstrated that loss of ARID1A expression occurs in endometriotic cyst epithelium adjacent to an ovarian endometrioid or clear cell carcinoma. 18 Similarly, decreased expression of ARID1A was also found in atypical ductal hyperplasia of the breast as compared with normal breast tissue. 9 Thus, it appears that loss of ARID1A expression represents an early molecular event during tumor development in several types of female reproductive cancer.
The finding of a higher percentage of complete ARID1A loss in high-grade endometrioid carcinoma as compared with low-grade endometrioid carcinoma is consistent with a recent report on 214 endometrial endometrioid carcinomas. 13 However, it should be noted that the previous study 13 used tissue microarrays, whereas the current study used the whole-tissue sections to detect clonal loss, which is otherwise difficult to evaluate in tissue microarrays. Nevertheless, both studies suggest that ARID1A loss is not only important during tumor initiation but also plays a role in tumor progression. In addition to inactivating mutations in ARID1A, molecular genetic alterations found in endometrioid carcinoma include mutations in PTEN, PIK3CA, KRAS, and CTNNB1 and microsatellite instability. 19 Mutations of PTEN have also been identified in endometrial hyperplasia, suggesting that PTEN mutation is an early event in endometrioid carcinoma. 20 It has become clear that PTEN deletion plays a critical role in tumor initiation, whereas TP53 mutation, ERBB2 overexpression or amplification, and CNKN2A inactivation likely represent late events and occur predominantly in grade 3 tumors. 21 High-grade endometrioid carcinomas have an increased frequency of mutations in several genes including PTEN and TP53 compared with low-grade endometrioid carcinomas. 22 High-grade endometrioid carcinoma can also arise de novo through TP53 mutation and HER2/neu amplification without progressing through a low-grade stage. 23 Indeed, on the basis of clinicopathologic and immunohistochemical studies, some high-grade endometrioid carcinomas exhibit overlapping features of low-grade endometrioid carcinoma and uterine serous carcinomas. 24 Several studies have investigated the relationship of ARID1A with other tumor suppressor genes in gynecologic cancers. In ovarian clear cell carcinoma, loss of ARID1A frequently coexists with PIK3CA mutation and occurs in the early stage of tumor development. 25, 26 In ovarian clear cell carcinoma and uterine endometrioid carcinoma, mutations in ARID1A occur exclusively in tumors with wild-type TP53. 15 Our preliminary data based on immunohistochemistry of the high-grade endometrioid carcinomas from the cohort in this study also showed a higher incidence of ARID1A loss in tumors without aberrant p53 expression (data not shown).
Although ARID1A staining pattern in endometrial lesions is either diffusely positive or completely negative in most cases, we observed a weak staining of ARID1A immunoreactivity (as compared with normal-appearing endometrial tissues) in a few CAH and endometrioid carcinoma cases. This finding may suggest that reduced expression of ARID1A probably due to inactivation in one of the ARID1A alleles is sufficient to contribute to tumor development. Future experiments are needed to determine whether ARID1A, like PTEN, is characterized by haploinsufficiency in its tumor suppressor functions.
This study also provided a unique opportunity to compare ARID1A expression between low-grade (grades 1 and 2) and high-grade (grade 3) endometrioid carcinomas from the same patient. Most concurrent low-grade and high-grade endometrioid carcinomas exhibited concordant expression pattern of ARID1A (complete loss, clonal loss, or no loss in both low-grade and high-grade tumor components), whereas approximately one fourth demonstrated a progression of loss (from retention or clonal loss to complete loss). These findings suggest that in at least some cases inactivation of the ARID1A pathway may participate in late progression from low-grade to high-grade uterine endometrioid carcinoma. The 2 cases showing an opposite pattern (clonal loss in low grade, retention in high grade) may reflect a sampling bias resulting from intratumoral heterogeneity of ARID1A inactivation.
In summary, we have performed a comprehensive analysis of ARID1A immunostaining in different stages of progression of uterine endometrioid carcinoma. The findings, together with our previous study, demonstrate a significant progressive increase in ARID1A loss moving from normal endometrium, to CAH, to low-grade endometrioid carcinoma, to high-grade endometrioid carcinoma. Our data suggest that loss of ARID1A expression (presumably due to a mutation) plays an important role in tumor progression in endometrioid carcinoma of the endometrium. Thus, it will be important to determine whether loss of ARID1A expression provides a molecular marker to predict tumor recurrence, treatment response, and overall survival in endometrioid carcinoma.
